Merck, Inc.
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- Conditions
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05406401
- Locations
- 🇰🇷
Seoul National University Hospital ( Site 0201), Seoul, Korea, Republic of
🇰🇷Samsung Medical Center ( Site 0200), Seoul, Korea, Republic of
🇨🇦BC Cancer Victoria-Clinical Trials Unit ( Site 0105), Victoria, British Columbia, Canada
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT05394350
- Locations
- 🇨🇭
Cantonal Hospital St.Gallen ( Site 0403), st.Gallen, Sankt Gallen, Switzerland
🇨🇭Ospedale Regionale Bellinzona e Valli ( Site 0400), Bellinzona, Ticino, Switzerland
🇩🇰Rigshospitalet ( Site 0500), Copenhagen, Hovedstaden, Denmark
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT05393037
- Locations
- 🇨🇱
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107), Santiago, Region M. De Santiago, Chile
🇿🇦Be Part Yoluntu Centre ( Site 0902), Paarl, Western Cape, South Africa
🇿🇦Josha Research ( Site 0900), Bloemfontein, Free State, South Africa
A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)
- Conditions
- Renal Impairment
- Interventions
- Drug: Molnupiravir
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05386758
- Locations
- 🇺🇸
Advanced Pharma CR, LLC ( Site 0004), Miami, Florida, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0005), Hallandale Beach, Florida, United States
🇺🇸Genesis Clinical Research, LLC ( Site 0003), Tampa, Florida, United States
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
- Conditions
- Hepatic Impairment
- Interventions
- Drug: Molnupiravir
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05386589
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ) ( Site 0002), Hollywood, Florida, United States
🇺🇸Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
🇺🇸Thomas Jefferson University - Pharmacology and Experimental Therapeutics ( Site 0001), Philadelphia, Pennsylvania, United States
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05382325
- Locations
- 🇮🇱
Rambam Health Care Campus-Oncology ( Site 0021), Haifa, Israel
🇮🇱Sheba Medical Center-ONCOLOGY ( Site 0020), Ramat Gan, Israel
🇳🇱Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037), Utrecht, Netherlands
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05347225
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital-hematology department ( Site 1002), Guangzhou, Guangdong, China
🇨🇳SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007), Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital-hematology department ( Site 1003), Zhengzhou, Henan, China
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05342636
- Locations
- 🇧🇷
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo, Sao Paulo, Brazil
🇫🇷Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille, Nord, France
🇫🇷Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest, Finistere, France
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05335005
- Locations
- 🇮🇱
Hadassah Medical Center-Clinical Reaserch Unit ( Site 0002), Jerusalem, Israel
🇷🇴ARENSIA Exploratory Medicine-Clinical Nephrology Hospital "Carol Davila" ( Site 0001), București, Bucuresti, Romania
🇺🇸Genesis Clinical Research, LLC ( Site 0003), Tampa, Florida, United States
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: AntihistamineDrug: H2 Receptor AntagonistDrug: Steroid Mouthwash (dexamethasone or equivalent)Drug: Supportive care measures
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05319730
- Locations
- 🇺🇸
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907), New York, New York, United States
🇮🇹IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 3207), Meldola, Emilia-Romagna, Italy
🇮🇹Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Site 3201), Milano, Italy